AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00403806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone 0.15 mg per kg bodyweight
Study NCT02553720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic activity plus conventional management
Description: walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
Study NCT00403806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Intravenous dexamethasone 0.5 mg per kg bodyweight
Study NCT00403806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous saline
Study NCT02553720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: aquatic activity plus conventional management
Description: walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
Study NCT04534426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: : Arnica montana
Description: In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
Study NCT01217047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling without FES
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
Study NCT01217047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
Study NCT04534426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucopolysaccharide polysulfate
Description: In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
Study NCT04534426 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: In Control group, only standard therapy was performed after surgery
Study NCT02154854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted half-dose
Study NCT02154854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted plain dose
Study NCT01217047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood assessment
Description: If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period.
Study NCT02490930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
Study NCT03302910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Stay Unit
Description: Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
Study NCT03302910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
Study NCT03250312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Osteopathic Manipulation
Description: The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
Study NCT00799461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
Study NCT00799461 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: internet-based intervention
Description: Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
Study NCT00799461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Completion of questions in an online format
Study NCT00799461 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: questionnaire administration
Description: Completion of questions in an online format
Study NCT04691596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-cue-contingent weekly incentives
Description: Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
Study NCT04691596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue-contingent weekly incentives
Description: Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
Study NCT04691596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Coaching
Description: Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Assessment and care of psychosocial aspects
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: psychosocial assessment and care
Description: Assessment and care of psychosocial aspects
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Evaluation of complications of treatment
Study NCT02144246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-hormonal period
Study NCT02144246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
Study NCT02155855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
Study NCT02155855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine care
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: assessment of therapy complications
Description: Evaluation of complications of treatment
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Managing therapy complications
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: management of therapy complications
Description: Managing therapy complications
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management
Description: Assessing and managing fatigue
Study NCT01257893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (acetylsalicylic acid)
Description: Aspirin one 81 mg capsule per day for 10-14 consecutive days
Study NCT01257893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
Study NCT03379493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1 ARTEMIS™ T cells
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
Study NCT02365064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirCurve 10 ASV
Description: Device is able to provide both ASV therapy and CPAP therapy modes.
Study NCT02365064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirCurve 10 ASV
Description: Device is able to provide both ASV therapy and CPAP therapy modes.
Study NCT01008527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 870,893
Description: Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
Study NCT01008527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Description: NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
Study NCT01008527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncovir poly IC:LC
Description: The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
Study NCT03994952 — intervention group
Intervention type: DEVICE
Intervention: Sway Balance Application
Description: Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
Study NCT03994952 — intervention group
Intervention type: DEVICE
Intervention: Balance Tracking Systems
Description: This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
Study NCT02363127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous progesterone
Description: subcutaneous progesterone 25 mg/day
Study NCT02363127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: vaginal progesterone in capsules 200 mg/3 times a day
Study NCT00348374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
Study NCT00348374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exubera
Description: Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
Study NCT00752362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Milennium Matrix® (Control)
Description: Percutaneous coronary intervention with bare metal stent
Study NCT00799461 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: fatigue assessment and management
Description: Assessing and managing fatigue
Study NCT00799461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Counseling provided via telephone
Study NCT03569917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal swab collection
Description: Rectab swab collection will be performed at inclusion and 5 and 30 days later.
Study NCT01423903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-51602
Description: A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
Study NCT00752362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinnium®
Description: Percutaneous coronary intervention with paclitaxel-eluting stent
Study NCT02988375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBTI
Study NCT02988375 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education
Study NCT00752362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supralimus®
Description: Percutaneous coronary intervention with sirolimus-eluting stent
Study NCT04343768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms.
Study NCT04343768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms.
Study NCT04343768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms.
Study NCT04343768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms.
Study NCT02046122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy.
Study NCT02046122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.
Study NCT02046122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLI
Description: HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10\^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.
Study NCT00397657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended release niacin
Description: Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
Study NCT00397657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: Ezetimibe 10mg once daily
Study NCT03795441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
Study NCT03835845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO7Y
Description: The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
Study NCT01371617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926
Description: Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
Study NCT04343768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: This drug will be only used in Arm 1.
Study NCT04343768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1B
Description: This drug will be only used in Arm 2.
Study NCT04004208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea (Aflibercept, BAY86-5321)
Description: Solution in a sterile glass vial, Dose A, IVT injection.
Study NCT04004208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Transpupillary conventional laser ablative therapy
Study NCT00265005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alteplase
Description: Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
Study NCT02898675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrine
Description: Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
Study NCT02898675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement
Description: Only open flap debridement treatment the bone loss limitedly
Study NCT05051410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracanal cryotherapy using needle irrigation and EndoVac system
Description: a cold saline will be used as final irrigant in two groups but with different irrigation systems.
Study NCT05653011 — intervention group
Intervention type: OTHER
Intervention: Endoscopic biopsy
Description: When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions.
Study NCT02046876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physiotherapy Program
Description: Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Undergo surgical wound and physical activity monitoring
Study NCT01458249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Measurement
Description: Undergo physical activity measurement
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Measurement
Description: Undergo physical activity measurement
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies